
    
      Prospective, multi-center, open-label single-arm study designed to enroll 370 HBR patients
      (for at least 340 evaluable) at up to 20 centers in up to 2 European countries. 370 patients
      will receive a BioFreedomTM CoCr stent. All patients will be followed up for 2 years.
    
  